What a Year of MHRA Recalls Tells Hospital Procurement Teams

We publish a short alert note every time the MHRA issues a drug recall that is relevant to hospital and institutional buyers, because our customers ask us to source urgently around exactly these events. Eleven notices later, with recall dates running from 29 January through 30 March 2026, a pattern is visible that a single alert never shows on its own. Individually, each recall reads as a discrete safety event: a batch failed a test, a manufacturer identified an impurity, a label was missing a detail. Read together, they describe how the UK medicines supply chain actually behaves under stress, and what a procurement team should do differently as a result.

This is not a "what is a recall" explainer. It is an analysis of eleven real, published MHRA alerts we have tracked this year: what went wrong in each case, which safety classes and therapeutic areas keep reappearing, and the procurement response that follows from the pattern rather than from any single incident.

One point up front. Euro Biom is a UK MHRA-licensed wholesale exporter, WDA(H) 59239, GDP-compliant, supplying UK-licensed, MHRA-authorised finished medicines. We are not a manufacturer and not a regulatory consultancy, and nothing here is clinical or regulatory advice for a specific patient. Where we cite figures, such as the counts below, they come from a straightforward count of the notices we have published, and are a snapshot of what we have tracked rather than a claim about MHRA alert volumes as a whole.

How the MHRA Classifies a Drug Alert

The MHRA sorts drug alerts into four classes according to the level of risk to patients, plus a separate National Patient Safety Alert (NatPSA) designation that can sit alongside a Class 1 or Class 2 action and adds a formal NHS governance reporting requirement.

• Class 1 is issued where there is a reasonable probability that use of, or exposure to, a product will cause serious adverse health consequences or death. It demands immediate quarantine of all affected stock and cessation of use, with no acceptable delay. The only Class 1 alert in our set is the recall of quetiapine oral suspension, published as NatPSA/2026/002 on 29 January 2026, covering all batches from the manufacturer due to a potential overdose risk.
• Class 2 covers a potential for temporary or medically reversible adverse health consequences, or a probability of serious harm considered remote but not excluded. It still requires prompt quarantine and return, and it is the class that dominates our tracked alerts: six of the eleven, covering carmustine (EL(26)A/05), baclofen oral solution (EL(26)A/06), KidNaps melatonin oral solution (EL(26)A/09), ramipril (EL(26)A/11), Hibiwash antiseptic solution (EL(26)A/15), and human rabies immunoglobulin (EL(26)A/18, also a NatPSA).
• Class 3 applies to a defect not likely to present a significant hazard to health, but which still requires a stock check and appropriate action. Three of our eleven fall here: ibuprofen and ibucalm tablets (EL(26)A/07), MOVICOL Ease citrus powder (EL(26)A/08), and a Bayer notice covering multiple products at pharmacy and wholesaler level (EL(26)A/12).
• Class 4 is a caution or product-information notification rather than a recall of the medicine itself. Our one example is Dropodex eye drops (EL(26)A/10), where the product information omitted the phosphate concentration, a labelling and documentation issue rather than a defect in the medicine.

What that mix tells a procurement team is straightforward: the class tells you how fast to act and how completely to quarantine, but not how disruptive the recall will be to supply. A Class 3 packaging defect on a widely stocked generic is a stock-check inconvenience. A Class 2 recall of all batches from a manufacturer of a paediatric or neurological product used by a small number of patients on a stable regimen can be a genuine continuity emergency, even one rung below Class 1 on the safety scale.

The Eleven Alerts We Tracked in 2026

For reference, here is the full set in the order they were published.

We treat this as a working sample, not a statistically representative one. It reflects the alerts we chose to write up as relevant to institutional buyers, not the full population of MHRA alerts issued in the period. Even so, eleven real, independently verifiable notices are enough to see a shape in the data, set out in the next two sections.

The Recurring Failure Modes Behind These Alerts

Grouped by the reason each manufacturer or the MHRA gave, the eleven alerts fall into a small number of failure types, and no single type accounts for more than a third of the total.

• Stability failures (three alerts). Baclofen crystallising in solution, the KidNaps melatonin out-of-specification stability result, and the rabies immunoglobulin potency reduction all describe a product that changed, or was found to be changing, over its shelf life in a way the original testing did not anticipate or catch in time. This is the largest single group in our set.
• Manufacturing and out-of-specification errors (two alerts). Carmustine's out-of-specification test result and ramipril's precautionary recall for a potential manufacturing-site error both point to something going wrong in production or testing rather than in the finished product's stability over time.
• Contamination and impurity findings (two alerts). Hibiwash's microbial contamination, identified through routine monitoring at the manufacturing facility, and the Bayer notice's impurity above the acceptable limit are both quality-control catches rather than clinical incident reports, which is itself a point in favour of the monitoring systems that found them.
• Content or fill defect (one alert). MOVICOL Ease's low active-ingredient content in some units is a distinct issue from stability, a content-uniformity problem identified at or shortly after manufacture.
• Labelling and product-information defect (one alert). Dropodex's missing phosphate concentration is the one alert in our set that is purely a documentation issue rather than a defect in the medicine itself, which is exactly why it sits at Class 4.
• Packaging integrity (one alert). The foil perforations found in some ibuprofen and ibucalm blister packs are a physical packaging defect that can compromise the product inside rather than a formulation problem.
• Formulation or product-safety concern (one alert). The quetiapine oral suspension recall stands apart. The published notice describes a potential overdose risk rather than a stated batch-quality defect of the kind above, which is consistent with why it was escalated to the most serious class and a National Patient Safety Alert rather than treated as a standard batch recall.

The honest reading of this spread is that there is no single root cause a procurement team can insure against by watching one thing closely. Stability, manufacturing error, contamination, content, labelling and packaging each produced at least one recall in this sample. A continuity plan built around only one of these, say a plan that only checks for contamination, would have missed most of what actually happened in 2026.

Which Therapeutic Areas Were Most Disrupted

One cluster stands out in this sample. Quetiapine (an antipsychotic), baclofen oral solution (a spasticity treatment used in neurology) and the KidNaps melatonin oral solution (a paediatric sleep-disorder product) together account for three of the eleven alerts, and between them cover the only Class 1 event in the set. All three affect patients for whom abrupt loss of supply, not just the underlying quality defect, is itself a clinical risk: antipsychotic discontinuation, baclofen withdrawal and disrupted paediatric routines are each a real clinical concern in their own right, separate from the reason for the recall.

The remaining eight alerts spread across oncology (carmustine), cardiovascular (ramipril), gastroenterology (MOVICOL Ease), analgesia (ibuprofen), ophthalmology (Dropodex), infection control (Hibiwash) and post-exposure prophylaxis (rabies immunoglobulin), plus one Bayer notice covering unspecified products. No area beyond the CNS and neurology cluster repeats in our sample.

The stock-planning implication is specific rather than general. It is not that any one therapeutic area is inherently higher risk. It is that products used by small, clinically fragile patient populations, where discontinuation itself carries harm and alternative formulations are limited, deserve a documented continuity plan regardless of classification. A hospital that reviews its dispensing data for oral-liquid, paediatric and CNS lines against this pattern is doing something more useful than reacting to each alert as it lands.

A Recall Is a Supply Event as Much as a Safety Event

The MHRA classification system answers a safety question: how urgently must this stock be removed from use. It does not answer a supply question: what happens to the patients and prescriptions that depended on that stock once it is gone. Those two problems arrive in the same notice, and pharmacy and procurement teams must solve both, usually the same day.

A minority of the alerts in our set, including the quetiapine and the KidNaps melatonin recalls, covered all batches from a manufacturer rather than a single lot or a specific batch range. When that happens, checking expiry dates or batch numbers does not narrow the problem down. Every unit from that manufacturer is affected, and the question stops being "which boxes do I quarantine" and becomes "where does my next unit come from." That second question is the one that determines whether a recall resolves in days or drags into a genuine stock-out.

What Good Practice Looks Like

The alerts we have tracked are consistent with a small number of practical disciplines that reduce how much a recall disrupts supply, independent of what caused the recall in the first place.

• Know your notification route. MHRA alerts reach organisations through the Central Alerting System. Confirm who receives these, that it does not depend on one named individual, and that it triggers an immediate, documented action rather than sitting in an inbox.
• Have a quarantine procedure that can run the same day. Physical segregation, clear labelling and removal from active dispensing stock should not require a meeting to authorise. The gap between an alert landing and stock being quarantined is where risk accumulates.
• Keep batch-level traceability current. Several recalls in our set affected specific batches rather than a whole product line. Identifying affected stock, and the patients who received it, without a manual stock-take turns a Class 2 or Class 3 recall into a manageable task.
• Document a second source before you need one. For any line where interruption is clinically significant, know in advance where an alternative, licensed supply route sits and roughly how quickly it can move. This is the discipline that most directly determines whether a recall becomes a stock-out. Our supplier qualification approach and our guidance on sourcing hard-to-source medicines both speak to assessing and documenting that second source before an emergency, not during one.
• Do not treat single-sourcing as a cost decision only. Consolidating a critical line onto one manufacturer or wholesaler can be the right commercial choice most of the time, but it converts every recall risk into a supply risk for that line. Build that trade-off in consciously rather than by default.

How Single-Source Dependency Turns a Class 2 Recall into a Stock-Out

This is the mechanism worth naming explicitly, because it is where a routine, correctly handled recall becomes a genuine patient-care problem. A Class 2 recall on its own is manageable: quarantine the stock, notify the relevant clinicians, follow the manufacturer's return instructions. What turns it into a stock-out is not the recall itself, it is the absence of a qualified alternative supply route for that product at the moment the recall lands.

Several products in our set, including a paediatric oral solution, a spasticity treatment and a specialist immunoglobulin, are supplied by a limited number of manufacturers. When the sole or dominant source for a line like that issues a recall covering all batches, there may be no domestic stock anywhere in the supply chain to switch to. A pre-qualified, licensed secondary supply route, agreed and documented before the recall rather than sourced from scratch afterwards, is what closes that gap. This means treating continuity for clinically critical lines as something to design deliberately, the same way a stability or contamination control system is designed deliberately, rather than assembling it under pressure once the alert has already been issued.

For a UK institution facing exactly this situation, an MHRA-licensed wholesale exporter with a broad supplier base and shortage-supply experience can shorten the gap between "our usual source has recalled this product" and "we have a compliant alternative in hand." Our pages on drug shortage supply and emergency pharmaceutical supply describe how that route works for UK institutional buyers in practice.

How Euro Biom Supports Continuity

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, WDA(H) 59239, operating under GDP. We supply UK-licensed, MHRA-authorised finished medicines to hospitals, Ministries of Health, NGOs and licensed distributors, and we work regularly with procurement and pharmacy teams responding to exactly the kind of event described above: a recall, a manufacturer's stability failure, or a shortage that has removed a usual source from the supply chain with little warning.

We are not a manufacturer, a pharmacy or a regulatory consultancy, and none of this article is clinical guidance. What we can do is help a buyer identify available UK-licensed stock through the appropriate route when their usual line has been disrupted, and support the documentation a GDP-compliant, MHRA-licensed supply chain requires. Our full regulatory framework is set out on our compliance page.